Showing posts with label Carboplatin-PLD. Show all posts
Showing posts with label Carboplatin-PLD. Show all posts
Saturday, May 28, 2011
abstract: Effects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers
OBJECTIVES:
Currently, pegylated liposomal doxorubicin (PLD) is regarded as one of the standard treatment options in recurrent ovarian cancers (ROC). Bevacizumab has shown significant antitumor activity for ROC in single-agent or in combination with cytotoxic agents. We have conducted a preliminary study to investigate effects of combination of bevacizumab and PLD for heavily pretreated patients with ROC.
CONCLUSION:
The present investigation suggested that combination therapy with bevacizumab and PLD was active and well tolerated for patients with ROC. We recommend the regimen be evaluated in further clinical studies.
Monday, June 28, 2010
repost: abstract: (Yondelis) Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer. BJ Monk et al
Note: Reposted from June 9th to coincide with Editorial from JCO; multinational study plus: JCO link
Friday, March 19, 2010
Medical News: SGO: New Option for Recurrent Ovarian Cancer? - in "Carboplatin-PLD" Meeting Coverage, SGO
Source reference: Pujade-Lauraine E, et al "Pegylated liposomal doxorubicin and carboplatin versus paclitaxel and carboplatin in patients with platinum-sensitive ovarian cancer in late relapse" SGO 2010; Abstract SAS 2
Subscribe to:
Posts
(
Atom
)
